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httpicense.Abstract Introduction: Nuclear factor kappa B/p65 (NF-jB/p65) regulates the expression of
various molecules important in tumorigenesis as cyclooxygenase-2 (COX-2).
Aim: To study the immunohistochemical expression of NF-jB/p65 and COX-2 in NSCLC,
investigate the relationship between their expression and the clinicopathological parameters, evalu-
ate their prognostic value and clarify their impact on survival.
Patients and methods: FiftyNSCLCpatients were enrolled in this study and subjected to: full med-
ical history and physical examination, routine laboratory tests and CT chest. Fiberoptic bronchos-
copy was done and biopsies were taken from visible masses and 20 mucosal biopsies of the same
patients (as control); sent for histopathological and immunohistochemical examination using anti-
COX2 and anti-NF-jB/p65 antibodies. Themedian followupof patientswas 13 (range 4–22 months).
Results: Thirty six (72%) showed positive NF-jB/p65 expression, it was higher in squamous cell
carcinoma and adenocarcinoma than in normal biopsies. Adenocarcinoma showed higher NF-jB/
p65 positivity compared to squamous and large cell carcinomas. A signiﬁcant relationship was found
between NF-jB/p65 expression and overall survival.
Forty ﬁve (90%) showedpositiveCOX-2 expression, no expressionwas detected in normal biopsies.
COX-2 expression was signiﬁcantly higher in adenocarcinoma compared to squamous and large cell
carcinomas. NF-jB/p65 and COX-2 expression was signiﬁcantly correlated with advanced tumor.H. Abo El-Magd).
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194 G.H. Abo El-Magd et al.stage, lymph node metastasis and grade. A signiﬁcant positive relationship was found between NF-
jB/p65 and COX-2 expression.
Conclusion: NF-jB/P65 and COX-2 expression has a prognostic value in NSCLC, they are suit-
able targets for development of new lung cancer therapies; inhibition of NF-jB and COX-2 will aug-
ment the efﬁcacy of anticancer therapy.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Lung cancer is the leading cause of death worldwide. The non-
small cell lung cancer (NSCLC) accounts for 75–85% among
all lung cancers. The conventional treatment e.g. surgery,
radiotherapy and chemotherapy yields a dismal overall 5-year
survival of 14% which necessitates the development of new
treatment options [1].
An interesting implication for the presence of high levels of
nuclear factor kappa-B (NF-jB)/p65 expression in epithelial
tumors such as lung cancer is the ﬁnding reported from several
in vivo and in vitro studies that NF-jB inhibits chemotherapy-
induced apoptosis of tumor cells by regulating either directly
or indirectly the transcription of several genes whose protein
products have an antiapoptotic effect [2]. In particular, p65
activation is a predictive factor of resistance to neoadjuvant
chemotherapy in breast cancer patients [3].
The most common form of NF-jB is a heterodimer consist-
ing of p65 and p50. In most quiescent normal cells; the NF-jB
dimers are bound with and kept in the cytoplasm by inhibitor
of NF-jB that mask the nuclear localization sequence (NLS)
in the NF-jB proteins [4].
NF-jB regulates the expression of various molecules
important in tumorigenesis, such as matrix metalloproteinases,
cyclooxygenase-2 (COX-2), iNOS, chemokines, and inﬂamma-
tory cytokines, all of which promote tumor cell invasion and
angiogenesis [5].
With advances in cytogenetic and molecular biology, the
detection and analysis of tumor suppressor genes and onco-
genes may provide predictive values for prognosis and treat-
ment choice for NSCLC. Among these molecular markers,
COX-2 over expression is common in NSCLC [6].
Cyclooxygenase-2 is an inducible enzyme that can be acti-
vated by cytokines, growth factors, oncogenes and chemical
carcinogens. COX-2 is related to inﬂammation and carcino-
genesis. It has been shown that COX-2 contributes to carcino-
genesis by increasing the angiogenesis and invasiveness, and
inhibiting apoptosis. The carcinogenic effect of COX-2 is
mainly exerted through the increase of prostaglandin levels
e.g. PGE2 [7].
COX-2 inhibitor has been investigated in both pre-clinical
and clinical studies, and has shown synergistic effects with
radiation and chemtoxic drugs on tumor [1].
Aim of the work
To study the immunohistochemical expression of NF-jB/p65
protein and COX-2 in NSCLC patients, investigate the rela-
tionship between their expression and the clinicopathological
parameters, evaluate their prognostic value and clarify their
impact on survival in such patients.Patients and methods
Patients
This study was carried out on 50 cases of NSCLC and 20 nor-
mal bronchial mucosal biopsies taken from the same patients
(as control) at Chest and Clinical Oncology Departments,
Tanta university hospital and the patients were treated and fol-
lowed up during the period from December 2010 to April
2013. Written, informed consent was obtained from each pa-
tient before enrollment into the study.
All patients were subjected to the following:
(1) Complete medical history and physical examination
including a full neurologic examination, documentation
of the Eastern Cooperation Oncology Group (ECOG)
performance and weight loss.
(2) Routine laboratory tests: complete blood picture, liver,
kidney functions and biochemical testing
(3) Plain chest X ray postero-anterior view.
(4) Spirometry.
(5) CT chest with contrast (peripheral tumors were diag-
nosed by CT guided biopsy and sent for histopatholo-
gical examination).
(6) Fiberoptic bronchoscopy for inspection of the tracheo-
bronchial tree for vocal cord paralysis, subcarinal wid-
ening for staging, and biopsy taking.
The ﬁberoptic bronchoscopy (Model: Olympus BF type
P10, Tokyo, Japan) was done for diagnosis of central tumors
as follows:
 After fasting overnight, premedications were taken in the
form of 0.6 mg atropine sulfate intramuscular 30 min before
the procedure.
 Xylocaine spray 10% was used for local anesthesia for
upper airways.
 It was done via nasal route; Xylocaine solution 2% was
used to anesthetize vocal cords, trachea and lower airways.
 Visible tumor was biopsied, also multiple endobronchial
biopsies were taken from the other side of the bronchial tree
(as control); any biopsy with proved dysplastic changes was
discarded. The biopsies were obtained by forceps under
direct vision, carefully removed and placed in 10% forma-
line ﬁxative.
(7) Histopathological study: using hematoxylin and eosin
staining for routine evaluation of the histopathological
characteristics and grading of the studied tumors.
(8) Immunohistochemical study: 3 lm sections were depa-
rafﬁnized in xylene for 30 min and rehydrated with
graded alcohol series. Sections were then subjected to
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citrate buffer, pH 6.0 (Lab Vision catalog # AP-9003),
for 10 min followed by cooling at room temperature
for 20 min and rinsing with phosphate buffered saline
(PBS) for one minute. Endogenous peroxidase was
blocked by immersion of the sections in 3% hydrogen
peroxide solution for 10 min, then washing them in
PBS. Immunohistochemical staining was performed
using the UltraVision Detection Kit (TP-015-HD, Lab
Vision, USA) according to the manufacturer’s protocol.
Sections were incubated for 10 min with Ultra V block
to prevent non-speciﬁc background staining, followed
by rinsing the sections with PBS. Afterward, an over-
night incubation was done in a humidity chamber with
rabbit monoclonal anti-COX-2 antibody (Clone SP21,
Cat. No. RM-9121-R7, Ready to use, Lab Vision),
and rabbit polyclonal anti-NFkB/p65 (Rel A) Ab-1 anti-
body (Cat. No. RB-1638-R7, Ready to use, Lab Vision),
followed by washing in PBS.
Sections were then covered with 4–5 drops of UltraVision
biotinylated goat anti-polyvalent secondary antibody, incu-
bated at room temperature for 10 min, then washed in PBS, fol-
lowed by incubation with streptavidin peroxidase solution for
10 min at room temperature, then rinsing with PBS. Sections
were then covered for 15 min by adding one drop of 3-30-diami-
no-benzidine-tetra-hydrochloride (DAB) chromogen mixed
with 2 ml of DAB substrate. Finally, sections were counter-
stained with Mayer’s hematoxylin, dehydrated in alcohol and
mounted in di-n-butyl-phthalate-polystyrene-xylene (DPX).
As positive controls, sections from a case of colonic carcinoma
known to show over-expression of COX-2 antibody, and sec-
tions from a case of prostatic carcinoma known to show
over-expression of NF-jB/p65 antibody were used. Negative
controls were prepared by omission of the primary antibodies.Figure 1 NF-jB/p65 staining of a case of bronchogenic adeno-
carcinoma, showing nuclear expression in >10% of tumor cells
(Immunoperoxidase ·400).
Figure 2 NF-jB/p65 staining of a case of bronchogenic squa-
mous cell carcinoma, showing nuclear expression in >10% of
tumor cells (Immunoperoxidase ·400).Immunohistochemical evaluation and scoring
COX-2 expression was evaluated semiquantitatively according
to the gross percentage of cells demonstrating a distinct cyto-
plasmic immunohistochemical reaction.[8] The immunostained
samples were scored to display absent (0), weak (+), moderate
(++), or strong (+++) immunoreactivity [9].
Positivity of the tumor for NF-jB expression was deﬁned as
only distinct nuclear immunostaining, which is considered as
activated NF-jB [10].
Nuclear localization ofNF-jBwas categorized as positive or
negative, aswell as an overall proportion of cells (<1%, 1–10%,
and>10%) with positive nuclear staining in the studied ﬁeld at
100 magniﬁcation. A minimum of ﬁve different areas for each
specimen was evaluated, and the mean was assessed [11].
(9) Patients underwent computed tomographic scans of the
abdomen, magnetic resonance imaging of the brain and
radionuclide bone scans were performed when clinically
indicated. Each patient had a performance status of 2 or
lower on the ECOG scale and adequate hematologic
parameters were included in this study.
The clinical and pathological staging was determined
according to the international staging system [12] and accord-ingly standard treatment protocols and follow up schedules
based on published guidelines were selected [13].
Statistical analysis
The data were analyzed using SPSS 13.0 software package.
The correlation of NF-jB and COX-2 expression with differ-
ent clinicopathologic characteristics was analyzed with chi-
square test. The Kaplan–Meier method and Log-rank test
were used to analyze the correlation of patient survival with
NF-jB and COX-2 expression. Overall-survival was deﬁned
as the time from diagnosis to the date of death from any cause
or last follow-up. A signiﬁcance level of P< 0.05 was used.
Results
In the ﬁfty patients who were enrolled in this study; only three
out of 20 patients with early stage disease (stages I, II, IIIA)
underwent lobectomy while the remaining were medically
inoperable or refused surgery. Nine patients were assigned to
receive thoracic radiotherapy alone. Seventeen patients re-
ceived concurrent carboplatin/paclitaxel and thoracic radio-
therapy. While the majority of patients ([21]; stage IV)
received chemotherapy alone in the form of platinum-based
Figure 3 NF-jB/p65 staining of a case of bronchogenic large cell
carcinoma showing nuclear expression in 1–10% of tumor cells
(Immunoperoxidase ·400).
Table 1 Relationship between immunohistochemical expression of
NF-jB n (%
Negative
Age 660 7 (14%)
>60 7 (14%)
Sex Female 7 (14%)
Male 7 (14%)
Smoking Non smoker 6 (12%)
Smoker 8 (16%)
Stage I–II 7 (14%)
IIIA, IIIB 4 (8%)
IV 3 (6%)
Histopathology Adenocarcinoma 6 (12%)
Squamous 5 (10%)
Large 3 (6%)
Normal 14 (70%)
Grade Grade 1 4 (8%)
Grade 2 7 (14%)
Grade 3 3 (6%)
Performance status (ECOG) 0 5 (10%)
1 5 (10%)
2 4 (8%)
Weight loss No weight loss 7 (14%)
Weight loss 7 (14%)
Lymph nodes N0 4 (8%)
N1–3 10 (20%)
Chemotherapy Not received 11 (22%)
Received 3 (6%)
Thoracic radiotherapy Not received 10 (20%)
Received 4 (8%)
Concurrent chemoradiotherapy Not received 10 (20%)
Received 4 (8%)
Events Died 10 (20%)
Alive 4 (8%)
X2: Chi square.
196 G.H. Abo El-Magd et al.chemotherapy for advanced and metastatic diseases with palli-
ative radiotherapy for metastatic sites; no one received neoad-
juvant chemotherapy or radiotherapy. The median follow up
of patients was 13 months (range 4–22 months).
There were 29 (58%) out of 50 cases of NSCLC who were
diagnosed as adenocarcinoma, 13 (26%) cases as squamous
cell carcinoma, and 8 (16%) cases as large cell carcinoma.
Thirty six cases (72%) showed positive NF-jB/p65 expres-
sion (23 adenocarcinomas (46%), 8 squamous cell carcinomas
(16%), and 5 large cell carcinomas (10%)). Eighteen cases
(36%) showed positive expression in >10% (Figs. 1 and 2),
10 cases (20%) in 1–10% (Fig. 3), and 8 cases (16%) in
<1% of tumor cells. On the other hand, 14 cases (28%)
showed negative expression for NF-jB/p65 (Table 1).
The NF-jB/p65 expression in NSCLC was signiﬁcantly
correlated with more advanced tumor stage (stages III and
IV) and lymph node metastasis (Table 1).NF-jB and clinicopathologic features in the studied cases.
) Chi-square
Positive
<1% 1–10% >10% X2 P-value
5 (10%) 2 (4%) 2 (4%) 10.128 0.018
3 (6%) 8 (16%) 16 (32%)
3 (6%) 3 (6%) 1 (2%) 9.361 0.025
5 (10%) 7 (14%) 17 (34%)
4 (8%) 3 (6%) 1 (2%) 9.142 0.027
4 (8%) 7 (14%) 17 (34%)
3 (6%) 2 (4%) 0 (0%) 25.948 0.000
5 (10%) 3 (6%) 5 (10%)
0 (0%) 5 (10%) 13 (26%)
6 (12%) 6 (12%) 11 (22%) 21.700 0.009
2 (4%) 2 (4%) 4 (8%)
0 (0%) 2 (4%) 3 (6%)
6 (30%) 0 (0%) 0 (0%)
1 (2%) 0 (0%) 0 (0%) 27.165 0.000
7 (14%) 6 (12%) 4 (8%)
0 (0%) 4 (8%) 14 (28%)
1 (2%) 0 (0%) 0 (0%) 24.018 0.001
6 (12%) 7 (14%) 4 (8%)
1 (2%) 3 (6%) 14 (28%)
4 (8%) 5 (10%) 3 (6%) 5.825 0.120
4 (8%) 5 (10%) 15 (30%)
2 (4%) 0 (0%) 0 (0%) 10.944 0.012
6 (12%) 10 (20%) 18 (36%)
8 (16%) 5 (10%) 5 (10%) 18.348 0.000
0 (0%) 5 (10%) 13 (26%)
5 (10%) 8 (16%) 18 (36%) 9.795 0.020
3 (6%) 2 (4%) 0 (0%)
3 (6%) 7 (14%) 13 (26%) 3.279 0.351
5 (10%) 3 (6%) 5 (10%)
6 (12%) 5 (10%) 5 (10%) 8.353 0.039
2 (4%) 5 (10%) 13 (26%)
Figure 6 COX-2 staining of a case of bronchogenic squamous
cell carcinoma showing strong (+++) cytoplasmic expression
(Immunoperoxidase ·400).
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adenocarcinoma was higher than that in the normal lung tissue
(P< 0.01); and the NF-jB/p65 expression in adenocarcinoma
was higher compared to that in squamous and large cell carci-
nomas (P< 0.01).
NF-jB/p65 expression was signiﬁcantly related to the pa-
tients’ age, sex, smoking, histopathological type, tumor grade,
tumor stage and performance status (P< 0.05).
The median survival time was 17.27, 16 and 7 months for
1%, 1–10% and >10% NF-jB positive patients respectively;
whereas the survival time was 17.77 months for patients with
NF-jB negative expression with a signiﬁcant correlation
(Fig. 4).
Forty ﬁve cases (90%) showed positive COX-2 expression
(29 adenocarcinomas (58%), 10 squamous cell carcinomas
(20%), and 6 large cell carcinomas (12%)). Twenty one cases
(42%) showed (+++) expression (Figs. 5 and 6), 13 cases
(26%) showed (++) expression (Fig. 7) and 11 cases (22%)
showed (+) expression. On the other hand, 5 cases (10%)
showed negative COX-2 expression. No expression of COX-
2 was detected in normal lung tissue. COX-2 expression in
NSCLC patients signiﬁcantly correlated with advanced tumor
stage (stages III and IV) and lymph node metastasis (Table 2).Survival Functions
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Figure 4 Prognostic importance of NF-jB expression on
NSCLC patients. Kaplan–Meier curve shows patient survival
according to survivin expression.
Figure 5 COX-2 staining of a case of bronchogenic
adenocarcinoma showing strong (+++) cytoplasmic expression
(Immunoperoxidase ·400).
Figure 7 COX-2 staining of a case of bronchogenic large cell
carcinoma showing moderate (++) cytoplasmic expression
(Immunoperoxidase ·400).All the studied cases of adenocarcinoma (100%) showed
positive COX-2 expression, which was signiﬁcantly higher than
that in squamous and large cell carcinomas (P< 0.01).
COX-2 expression was signiﬁcantly related to the patients’
sex, histopathological type, tumor grade, tumor stage, nodal
metastasis and performance status (P< 0.05).
The median survival time was 15.09, 15.86 and 11 months
for (+), (++) and (+++) COX-2 positive patients respec-
tively whereas the survival time was 15.670 months for patients
with COX-2 negative expression with no signiﬁcant correlation
(Fig. 8).
A signiﬁcant positive relationship was found between
COX-2 and NF-jB/P65 immunohistochemical expression in
NSCLC (X2 = 58.682, P=<0.001) (Table 3).
Discussion
The p65 subunit of NF-jB is responsible for the transactiva-
tion of downstream genes involved in the regulation of cell sur-
vival, cell cycle distribution, and apoptosis [14]. Wang et al.
[15] concluded that p65 expression has a protective role against
celecoxib-mediated cell death of human breast cancer.
There is a close relationship between the transcription fac-
tor NF-jB and regulation and control of cellular proliferation
Table 2 Relationship between the immunohistochemical expression of COX-2 and clinicopathologic features in the studied cases.
COX-2 n (%) Chi-square
Negative Positive
(+) (++) (+++) X2 P-value
Age 660 3 (6%) 5 (10%) 4 (8%) 4 (8%) 4.300 0.231
>60 2 (4%) 6 (12%) 9 (18%) 17 (34%)
Sex Female 3 (6%) 5 (10%) 4 (8%) 2 (4%) 8.150 0.043
Male 2 (4%) 6 (12%) 9 (18%) 19 (38%)
Smoking Non smoker 2 (4%) 5 (10%) 4 (8%) 3 (6%) 4.134 0.247
Smoker 3 (6%) 6 (12%) 9 (18%) 18 (36%)
Stage I–II 3 (6%) 8 (4%) 1 (2%) 0 (0%) 34.864 0.000
IIIA, IIIB 0 (0%) 2 (4%) 8 (4%) 7 (14%)
IV 2 (4%) 1 (2%) 4 (8%) 14 (28%)
Histopathology Adenocarcinoma 0 (0%) 8 (16%) 6 (12%) 15 (30%) 39.574 <0.001
Squamous 3 (6%) 2 (4%) 4 (8%) 4 (8%)
Large 2 (4%) 1 (2%) 3 (6%) 2 (4%)
Normal 20 (100%) 0 (0%) 0 (0%) 0 (0%)
Grade Grade 1 1 (2%) 4 (8%) 0 (0%) 0 (0%) 20.970 0.002
Grade 2 3 (6%) 6 (12%) 8 (16%) 7 (14%)
Grade 3 1 (2%) 1 (2%) 5 (10%) 14 (28%)
Performance status (ECOG) 0 3 (6%) 2 (4%) 1 (2%) 0 (0%) 24.164 0.000
1 0 (0%) 8 (16%) 7 (14%) 7 (14%)
2 2 (4%) 1 (2%) 5 (10%) 14 (28%)
Weight loss No weight loss 3 (6%) 4 (8%) 7 (14%) 5 (10%) 4.258 0.235
Weight loss 2 (4%) 7 (14%) 6 (12%) 16 (32%)
Lymph nodes N0 3 (6%) 3 (6%) 0 (0%) 0 (0%) 17.071 0.001
N1–3 2 (4%) 8 (16%) 13 (26%) 21 (42%)
Chemotherapy Not received 3 (6%) 10 (20%) 9 (18%) 7 (14%) 11.815 0.008
Received 2 (4%) 1 (2%) 4 (8%) 14 (28%)
Thoracic radiotherapy Not received 4 (8%) 4 (8%) 12 (24%) 21 (42%) 20.664 0.000
Received 1 (2%) 7 (14%) 1 (2%) 0 (0%)
Concurrent chemoradiotherapy Not received 5 (10%) 9 (18%) 5 (10%) 14 (28%) 9.616 0.022
Received 0 (0%) 2 (4%) 8 (16%) 7 (14%)
Events Died 3 (6%) 8 (16%) 7 (14%) 8 (16%) 3.759 0.289
Alive 2 (4%) 3 (6%) 6 (12%) 13 (26%)
X2: Chi square.
198 G.H. Abo El-Magd et al.and tumorigenesis [16]. NF-jB is also implicated in cancer
development and progression [17].
Tumor cells often use NF-jB to achieve resistance to anti-
cancer drugs and radiation; inhibition of NF-jB activation ap-
pears as a promising option to improve the efﬁcacy of
conventional anti-cancer therapies [18].
In the present study, there were 36 cases; 72% showed po-
sitive NF-jB/p65 expression. In agreement with our ﬁndings,
Tang et al. 2006 [19] found high levels of NF-jB/p65 nuclear
expression in the majority (54%) of NSCLCs which warrants
the evaluation of this marker as a predictor of chemotherapy
or radiotherapy response in lung cancer. Another study also
evaluated the expression of NF-jB in 71 specimens from
NSCLC patients and showed that nuclear positive rate was
67.6% [20].
In this study, NF-jB/p65 expression in NSCLC signiﬁ-
cantly correlated with advanced tumor stage (stages III and
IV) and lymph node metastasis. In accordance with the presentstudy, Tang et al. [19] found that NF-jB/p65 expression in
lung adenocarcinomas signiﬁcantly correlated with more
advanced tumor stage (stages III and IV) and, in particular,
locally advanced tumors and lymph node metastasis.
Tumor-induced activity of COX-2 and related downstream
enzymes e.g. PGE2 has been implicated to play a crucial role to
enhance tumor invasion and metastasis, angiogenesis,
decreased host immunity, and resistance to apoptosis [9].
The tumor-associated upregulation of COX-2 expression
may be regarded as a particular feature of tumorigenesis and
development of an invasive type of NSCLC correlating with
high levels of COX-2 expression in lymph node metastases of
human lung tumors [21].
The current study, in accordance with multiple published
reports [1,7,9,22–24] demonstrate an increased expression of
COX-2 in NSCLC, particularly in adenocarcinomas; which
was signiﬁcantly higher compared to its expression in squa-
mous cell and large cell carcinomas. This might provide a basis
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Figure 8 Prognostic importance of COX-2 expression on
NSCLC patients. Kaplan–Meier curve shows patient survival
according to survivin expression.
Table 3 Relationship between COX-2 and NF-jB/p65 immu-
nohistochemical expression in non-small cell lung cancer.
NF-jB n (%) COX-2 n (%)
Negative (+) (++) (+++)
Negative 5 (10%) 6 (12%) 3 (6%) 0 (0%)
1% 0 (0%) 3 (6%) 5 (10%) 0 (0%)
1–10% 0 (0%) 2 (4%) 4 (8%) 4 (8%)
>10% 0 (0%) 0 (0%) 1 (2%) 17 (34%)
Chi-square X2 58.682
P-value <0.001
X2: Chi square.
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agreement with this study; Li et al. [1] found signiﬁcant
COX-2 expression in NSCLC than normal lung tissue (0%).
The present study could not detect a correlation between
COX-2 expression and survival; this is in agreement with Turk
et al. and Marrogi et al. [7,25].
It has been reported that non steroidal anti-inﬂammatory
drugs (NSAID) increase the cytotoxic effect of the radiother-
apy and chemotherapy [26]. In clinical studies, celecoxib, a
selective COX-2 inhibitor, has increased the response rate of
paclitaxel and carboplatine administered preoperatively in
the NSCLC patients [27,28].
In a phase II study by Edelman et al. [29] survival was sig-
niﬁcantly better when COX-2 inhibitor celecoxib was added to
the chemotherapy compared to chemotherapy only in ad-
vanced stage NSCLC patients showing increased COX-2
expression. Fidler et al. [30] also reported a better survival in
lung cancer patients with COX-2 overexpression treated with
second line decotaxel and celecoxib compared with the patients
without COX-2 expression. In these patients with poor prog-
nosis, COX-2 expression can be a target for treatment. Fur-
thermore, selective COX-2 inhibitors have the potential to
inhibit tumor angiogenesis and metastasis and can be used
for long-term maintenance treatment.
Like the results of this study, Zhang et al. [20] found that
the expression level of NF-jB in poorly or moderatelydifferentiated lung cancer cells was higher than that in well-dif-
ferentiated ones.
In a study of Jianqun et al. [31] there was a high expression
of NF-jB in the poorly-differentiated lung cancer cells (28
cases), and a low expression in the well-differentiated lung can-
cer cells (17 cases), t= 3.640, P= 0.001 which might also be
one of the reasons for NSCLC tolerance to chemotherapy
and poor prognosis.
This study showed that the NF-jB expression in squamous-
cell carcinoma and adenocarcinoma was higher than that in
normal lung tissue; and the NF-jB expression in adenocarci-
noma was higher compared to that in quamous-cell carcinoma,
this is in agreement with the study of Zhang et al. [32].
The NF-jB/p65 was signiﬁcantly related to the patients’
age, sex, smoking, histopathological type, tumor grade, tumor
stage and performance status (P< 0.05). Cigarette smoke
condensate induced the expression of the NF-jB-regulated
proteins COX-2 and celecoxib abolished the induction, this ex-
plains the relation between NF-jB and smoking [5]. In con-
trast, Jianqun et al. [31] found that NF-jB was not related
to the patients’ age, gender, stage, size and site of the tumor,
or pathological type, P> 0.05.
Zhang et al. [20] concluded that immunohistochemical
expression NF-jB in patients with NSCLC was an indepen-
dent prognostic factor for overall survival; this is in agreement
with this study. On the other hand, Tang et al. [19] concluded
that there was no correlation detected between NF-jB/p65
expression and overall survival.
In this study, a signiﬁcant positive relationship was found
between COX2 and NF-jB immunohistochemical expression
in NSCLC, this is in accordance with the study published by
Zhang et al. [20] This can be explained by the fact that NF-
jB activation directly exerts transcriptional regulation of
COX-2 [19].Conclusion
NF-jB/P65 and COX2 expression has a prognostic value in
NSCLC and they are suitable targets for the development of
new lung cancer therapies. It is assumed that inhibition of NF-
jB and COX-2 will augment the efﬁcacy of anticancer therapy.
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